Erschienen in:
24.06.2023 | Short Communication
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients
verfasst von:
M. Valery, K. Saleh, R. Ecea, J. M. Michot, V. Ribrag, K. Fizazi, A. Hollebecque, A. Lecesne, S. Ponce, Y. Loriot, S. Champiat, C. Baldini, C. Sarkozy, C. Castilla-Llorente
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 3/2023
Einloggen, um Zugang zu erhalten
Abstract
Background
Cytokine release syndrome (CRS) is a common adverse event of CAR T cell or bispecific antibody (bsAb) therapy. Anti-IL6/IL6R drugs are used in the management of auto-immune diseases. Some reports showed increased risk of bacterial infection in this context. In onco-hematology, there are few data about the occurrence of infection after administration of an anti-IL6/IL6R for CRS.
Methods
We retrospectively reviewed all consecutive patients treated in Gustave Roussy Cancer Campus between 2018 and 2021, who received anti-IL6/IL6R for CRS due to bsAb in phase I clinical trials or adoptive cellular therapy (ACT). We constituted a control group including all the patients treated in the same clinical trials or standard of care ACT, naïve of anti-IL6/IL6R.
Results
Fifty-two patients have been included. In the anti-IL6/IL6R group (n = 26), five patients developed a grade 2 to 5 infection within a month after anti-IL6/IL6R treatment, including two grade 5 infections. In the control group (n = 26), only one patient had a grade 3 infection. The two patients who had grade 5 infections were treated for diffuse large B cell lymphoma (DLBCL), one with bsAb and the other with CAR T cell. Fifty percent (3/6) of DLBCL patients who received an anti-IL6/IL6R presented an infection, one of which was a grade 5. In solid tumor patients treated with bsAb and anti-IL6/IL6R, only one patient (/9, 11%) developed a grade 2 viral infection.
Conclusion
It seems that the use of anti-IL6/IL6R in CRS secondary to bsAb administration in solid tumors patients does not significantly increase the risk of infection, as opposed to DLBCL patients where secondary infection might be a concern.